I very rarely recommend anyone watch or participate in a meeting, so this is a BFD: If you care about cost effectiveness, I recommend that you
Gina Kolata had a recent piece in the NYT that took the CMS Innovation Center to task for not relying on randomized controlled trials more.
The following post is coauthored by Sarah Jane Reed, Sarah K. Emond, and Austin Frakt. Sarah Jane Reed serves as Program Director for the Institute for
In this week’s JAMA Internal Medicine, “Comparative Effectiveness of Intensity-Modulated Radiotherapy and Conventional Conformal Radiotherapy in the Treatment of Prostate Cancer After Radical Prostatectomy“: Importance
A faithful reader of the blog thought I might feel better if I focused on some actual clinical trials. He’s right. From JAMA, “Association of
A research notebook entry on an important paper follows. I’ve left out quite a bit that is more tutorial. So, the paper is more accessible
New manuscript in Health Affairs, “Health Care Cost Containment Strategies Used In Four Other High-Income Countries Hold Lessons For The United States“: Around the world,
I make the case for more prostate cancer comparative effectiveness research in a new post on the AcademyHealth blog. Check it out! @afrakt
Boston, Mass., November 19, 2012 – The Institute for Clinical and Economic Review (ICER) has posted the draft supplementary report “Diagnosis and Treatment of Obstructive Sleep Apnea
I serve on the New England Comparative Effectiveness Public Advisory Council (CEPAC), the purpose of which is to translate medical science for patients, clinicians, and
A Commonwealth Fund publication by David Squires summarizes the use of comparative effectiveness research to inform health policy in England, France, Germany, and Australia. The
A June 2009 Health Affairs paper by Ari Hoffman and Steven Pearson includes this typology of marginal medicine: (1) Inadequate evidence of comparative net benefit
